SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 73 filers reported holding SYNDAX PHARMACEUTICALS INC in Q1 2018. The put-call ratio across all filers is 1.65 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,541,153 | -87.6% | 106,140 | -82.1% | 0.00% | -75.0% |
| Q2 2023 | $12,442,090 | -55.4% | 594,462 | -55.0% | 0.00% | -55.6% |
| Q1 2023 | $27,882,212 | +86434.3% | 1,320,225 | +4.3% | 0.01% | -10.0% |
| Q4 2022 | $32,221 | -99.9% | 1,266,129 | +12.8% | 0.01% | 0.0% |
| Q3 2022 | $26,974,000 | +45.9% | 1,122,452 | +16.8% | 0.01% | +42.9% |
| Q2 2022 | $18,490,000 | +20.3% | 961,106 | +8.7% | 0.01% | +40.0% |
| Q1 2022 | $15,370,000 | -11.5% | 884,334 | +11.4% | 0.01% | 0.0% |
| Q4 2021 | $17,374,000 | +40.3% | 793,700 | +22.5% | 0.01% | +25.0% |
| Q3 2021 | $12,384,000 | +43.7% | 648,026 | +29.1% | 0.00% | +33.3% |
| Q2 2021 | $8,616,000 | -45.6% | 501,798 | -29.3% | 0.00% | -40.0% |
| Q1 2021 | $15,837,000 | -8.2% | 709,639 | -8.5% | 0.01% | -16.7% |
| Q4 2020 | $17,253,000 | +36.9% | 775,708 | -9.2% | 0.01% | +20.0% |
| Q3 2020 | $12,603,000 | -3.7% | 853,968 | -3.3% | 0.01% | -16.7% |
| Q2 2020 | $13,089,000 | +34.3% | 883,236 | -0.6% | 0.01% | +20.0% |
| Q1 2020 | $9,746,000 | +18.3% | 888,516 | -5.3% | 0.01% | +66.7% |
| Q4 2019 | $8,235,000 | +15.2% | 937,961 | -2.0% | 0.00% | 0.0% |
| Q3 2019 | $7,149,000 | -18.7% | 956,940 | +1.3% | 0.00% | 0.0% |
| Q2 2019 | $8,792,000 | +84.5% | 944,450 | +4.0% | 0.00% | +50.0% |
| Q1 2019 | $4,766,000 | +32.2% | 907,853 | +12.1% | 0.00% | 0.0% |
| Q4 2018 | $3,605,000 | -43.9% | 810,184 | +1.8% | 0.00% | 0.0% |
| Q3 2018 | $6,428,000 | +63.9% | 795,767 | +42.4% | 0.00% | 0.0% |
| Q2 2018 | $3,922,000 | -30.7% | 558,725 | +40.5% | 0.00% | 0.0% |
| Q1 2018 | $5,658,000 | +188.7% | 397,579 | +77.7% | 0.00% | +100.0% |
| Q4 2017 | $1,960,000 | +202.9% | 223,758 | +304.8% | 0.00% | – |
| Q3 2017 | $647,000 | +237.0% | 55,280 | +302.2% | 0.00% | – |
| Q2 2017 | $192,000 | – | 13,743 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,600,000 | $52,272,000 | 8.55% |
| Foresite Capital Management IV, LLC | 875,000 | $12,705,000 | 7.06% |
| Aisling Capital Management LP | 1,025,000 | $14,883,000 | 6.13% |
| Saturn V Capital Management LP | 807,969 | $11,731,710 | 4.91% |
| Eversept Partners, LP | 2,596,245 | $37,697,477 | 3.19% |
| ACUTA CAPITAL PARTNERS, LLC | 297,035 | $4,312,948 | 2.89% |
| Paradigm Biocapital Advisors LP | 2,390,077 | $34,703,918 | 2.36% |
| DAFNA Capital Management LLC | 458,373 | $6,655,576 | 2.07% |
| SPHERA FUNDS MANAGEMENT LTD. | 773,061 | $11,224,846 | 2.04% |
| PFM Health Sciences, LP | 2,715,235 | $39,425,212 | 1.86% |